Thieme E-Journals - Brazilian Journal of Oncology / Abstract
Download PDF
Open Access
CC BY 4.0 · Brazilian Journal of Oncology 2026; 22: s00461817026
DOI: 10.1055/s-0046-1817026
Original Article
Clinical Oncology

Radionuclide Therapy for Bone Pain in Cancer Patients in Brazil (2015–2023): A Comparative Analysis of Public and Private Health Systems in the Context of the COVID-19 Pandemic

Authors

  • Fabricius Rocha Cardoso 

    1   Nuclear Medicine Service, Clínica Felippe Mattoso, Unidade Hospital Samaritano, Rio de Janeiro, RJ, Brazil
    2   PET-CT Service, Hospital Unimed, Volta Redonda, RJ, Brazil

Funding The author declares that he did not receive funding from agencies in the public, private or nonprofit sectors to conduct the present study.
Further Information
  Permissions and Reprints All articles of this category

Abstract

Introduction

Bone metastases are common in advanced cancer and often result in severe pain. Radionuclide therapy with Beta-emitting radiopharmaceuticals, such as samarium-153 and strontium-89, is a recognized option for palliative management. The coronavirus disease 2019 (COVID-19) pandemic disrupted oncology care worldwide, including access to nuclear medicine services in Brazil.

Materials and Methods

The present retrospective observational study analyzed administrative data from the Computer Sciences Department of the Brazilian Unified Health System (Departamento de Informática do Sistema Único de Saúde, DATASUS, in Portuguese) and the Data Pannel of the Information Exchange in Supplementary Health Pattern (Painel de Dados do Padrão de Troca de Informações na Saúde Suplementar, D-TISS, in Portuguese) of the Brazilian National Supplementary Health Agency (Agência Nacional de Saúde Suplementar, ANS, in Portuguese). We included procedures for Beta-emitting radionuclide therapy for bone pain from January 2015 to December 2023, identified using the codes of the Management System of the Table of Procedures, Medications, and Orthoses, Prostheses and Auxiliary Means of Locomotion of the SUS ((Sistema de Gerenciamento da Tabela de Procedimentos, Medicamentos e OPM do SUS, SIGTAP, in Portuguese) and of the Unified Supplementary Health Terminology (Terminologia Unificada da Saúde Suplementar, TUSS, in Portuguese). Monthly procedure counts were analyzed by health sector across 3 periods: prepandemic (January 2015–February 2020), pandemic (March 2020–December 2022), and postpandemic (2023). Data were expressed as median and interquartile range (IQR) values due to data skewness. The time-series modeling estimated expected trends; observed and expected counts were compared using non-parametric tests.

Results

A total of 434 procedures were recorded in the SUS, and 749, in the Supplementary Health system. No significant difference was found between systems prior to the pandemic (median procedures/month: SUS – 7 [IQR: 1–11]; Supplementary Health – 5 [IQR: 0–11]; p = 0.21). During the pandemic, SUS volumes declined sharply, with no recorded procedures in 2023 (median during the pandemic: 0 [IQR: 0–0]). The private sector maintained higher levels (median: 9 [IQR: 7–12]). Compared to projections, the SUS showed a significant shortfall (p = 0.000000000116), while the Supplementary Health remained statistically aligned (p = 0.62). A direct comparison of the magnitude of the decline showed a significantly greater reduction in the public system.

Conclusion

The pandemic caused a sharp sustained reduction in the access to radionuclide therapy for bone pain in Brazil's public health system, exposing systemic vulnerabilities that emphasize the need for resilient cancer care policies.

Keywords

bone metastases - nuclear medicine - radionuclide therapy - COVID-19 - public health - administrative data - supplementary health


Publication History

Received: 03 April 2025

Accepted: 11 December 2025

Article published online:
24 March 2026

© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil

Bibliographical Record
Fabricius Rocha Cardoso. Radionuclide Therapy for Bone Pain in Cancer Patients in Brazil (2015–2023): A Comparative Analysis of Public and Private Health Systems in the Context of the COVID-19 Pandemic. Brazilian Journal of Oncology 2026; 22: s00461817026.
DOI: 10.1055/s-0046-1817026
 

  • References

  • 1 Mercadante S, Klepstad P, Kurita GP, Hjermstad MJ, Sloan P, Caraceni A. Multidisciplinary approach to pain management in cancer patients: a European Society of Medical Oncology (ESMO) position paper. Ann Oncol 2018; 29 (Suppl. 04) iv16-iv21
    Search in Google Scholar
  • 2 Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010; 40 (02) 89-104
    Search in Google Scholar
  • 3 Etchebehere EC, Pereira Neto CA, Lima MC. et al. Treatment of bone pain secondary to metastases using samarium-153-EDTMP. Sao Paulo Med J 2004; 122 (05) 208-212
    Search in Google Scholar
  • 4 Sapienza MT, Ono CR, Guimarães MIC, Watanabe T, Costa PA, Buchpiguel CA. Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy. Rev Hosp Clin Fac Med Sao Paulo 2004; 59 (06) 321-328
    Search in Google Scholar
  • 5 Resche I, Chatal JF, Pecking A. et al. A dose-controlled study of 153Sm-EDTMP in the treatment of patients with painful bone metastases. Eur J Cancer 1997; 33 (10) 1583-1591
    Search in Google Scholar
  • 6 Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46 (Suppl. 01) 38S-47S
    Search in Google Scholar
  • 7 Fischer M, Kampen WU. Radionuclide Therapy of Bone Metastases. Breast Care (Basel) 2012; 7 (02) 100-107
    Search in Google Scholar
  • 8 Maringe C, Spicer J, Morris M. et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 2020; 21 (08) 1023-1034
    Search in Google Scholar
  • 9 Araujo SEA, Leal A, Centrone AFY. et al. Impact of COVID-19 pandemic on care of oncological patients: experience of a cancer center in a Latin American pandemic epicenter. Einstein (Sao Paulo) 2020; 19: eAO6282
    Search in Google Scholar
  • 10 Freudenberg LS, Paez D, Giammarile F. et al. Global Impact of COVID-19 on Nuclear Medicine Departments: An International Survey in April 2020. J Nucl Med 2020; 61 (09) 1278-1283
    Search in Google Scholar
  • 11 Sud A, Jones ME, Broggio J. et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol 2020; 31 (08) 1065-1074
    Search in Google Scholar
  • 12 Discontinuance report for Metastron (strontium [89Sr] chloride injection). Health Canada, Drug Shortages Canada. . Available from: https://www.drugshortagescanada.ca/discontinuance/63929 . Accessed 23 Jul 2025
  • 13 Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). Voto n° 183/2022/SEI/DIRE5/ANVISA. Analisa a proposta de abertura de processo regulatório e de Resolução da Diretoria Colegiada que prorroga a vigência da Resolução da Diretoria Colegiada n° 567, de 29 de setembro de 2021. Brasília: ANVISA; 2022. . Disponível em: https://www.gov.br/anvisa/pt-br/composicao/diretoria-colegiada/reunioes-da-diretoria/votos/2022/copy3_of_rop-20-2022/itens-2-1-1-e-2-4-9-voto-183-2022-dire5.pdf . Accessed 23 Jul 2025
    Search in Google Scholar
  • 14 Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária (ANVISA). Resolução - RDC n° 567, de 29 de setembro de 2021. Dispõe sobre os critérios e procedimentos temporários e excepcionais para importação de radiofármacos industrializados constantes na Instrução Normativa n° 81, de 16 de dezembro de 2020, da ANVISA. Brasília: Diário Oficial da União; 2021. . Available from: https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=RDC&numeroAto=00000567&seqAto=000&valorAno=2021&orgao=RDC/DC/ANVISA/MS&codTipo=&desItem=&desItemFim=&cod_menu=1696&cod_modulo=134&pesquisa=true
    Search in Google Scholar